Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
SOUTH SAN FRANCISCO, Calif., Aug. 21, 2017 -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that on August 18, 2017, the compensation committee of the Company's board of directors granted nine new employees options to purchase an aggregate of 56,725 shares of the Company's common stock and 22,364 restricted stock units. Each stock option has an exercise price per share equal to $18.22, which was the closing trading price on the date of the grant. The stock options and restricted stock units were granted pursuant to the Company's 2014 Employment Commencement Incentive Plan, which was approved by the Company's board of directors in December 2014 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
About Achaogen
Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. The Food and Drug Administration has granted plazomicin Breakthrough Therapy designation for the treatment of bloodstream infections caused by certain Enterobacteriaceae in patients who have limited or no alternative treatment options. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. The Company’s second product candidate is C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination. Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections and additional disease areas. All product candidates are investigational only and have not been approved for commercialization. For more information, please visit www.achaogen.com.
Investor Contact: Matthew Duffy 212.915.0685 [email protected] Media Contact: David Arrington Vice President, Investor Relations and Corporate Communications 650.440.5856 [email protected]
